DEA Notice: USP Seeks to Import Marihuana for Analytical Standards

You might care about this because the Drug Enforcement Administration (DEA) has issued a public notice about an application from the United States Pharmacopeial Convention (USP). USP wants to become a registered importer of certain controlled substances, specifically marihuana extract and marihuana. This application is important because it allows USP to import these substances for a very specific purpose: to create analytical reference standards. These standards are used by other organizations to test raw materials. The DEA's notice explains that this registration would not allow USP to import finished drug products for commercial sale. It also sets out the process for other registered bulk manufacturers or applicants to submit comments or objections to this request. They have until July 30, 2026, to do so. This helps ensure transparency and allows interested parties to weigh in on who gets to handle controlled substances for research and quality control. What is particularly interesting about this notice is the specific nature of the substances involved: marihuana and marihuana extract, both listed under Schedule I controlled substances. Schedule I drugs are considered to have a high potential for abuse and no currently accepted medical use, which makes their handling and importation highly regulated. This application highlights a specialized but important aspect of drug control where even these substances are needed for scientific purposes. USP's role is to provide standards for quality, purity, strength, and consistency of medicines and other healthcare products. Allowing them to import these substances for analytical reference standards ensures that other researchers and manufacturers can accurately test cannabis-related products or raw materials. This is not about selling marijuana products commercially. Instead, it is about setting benchmarks for scientific accuracy and quality control in a highly regulated area, which is a unique and important aspect of this notice. People who would be most interested in this legal document include pharmaceutical companies that work with controlled substances, especially those researching or developing cannabis-related products. Quality control laboratories and analytical testing facilities would also find this relevant, as they rely on accurate reference standards for their work. Researchers in the fields of pharmacology, toxicology, and drug development would also be keen to understand the process for importing controlled substances for scientific use. The Drug Enforcement Administration and other federal agencies involved in drug regulation would obviously be key stakeholders. Additionally, legal professionals specializing in drug policy, import regulations, or controlled substance laws would find the procedural details and the specific conditions for registration to be important. Anyone involved in setting or using drug quality standards, particularly for Schedule I substances, would also want to be aware of this application.